ArticleWorld journal of oncology2026
Siglec-15 Expression in Gastric Carcinoma and Its Association With Clinicopathological Variables.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer remains the fifth most common malignancy worldwide and is often diagnosed at advanced stages with limited treatment options. Although immunotherapy targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) has improved outcomes in several cancers, many patients exhibit resistance, necessitating alternative therapeutic strategies. Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15), a recently recognized immune suppressor, is overexpressed in tumor cells and tumor-associated macrophages (TAMs), and is largely absent from normal tissues, making it a promising immunotherapy target. Methods: This tissue microarray (TMA) study retrospectively collected formalin-fixed paraffin-embedded (FFPE) tissue specimens from 2015 to 2019 for 77 gastric cancer patients from King Hussein Cancer Center. Siglec-15 expression patterns in tumor cells and TAMs were analyzed and compared with clinicopathological features and patient outcomes. Survival was assessed using Kaplan-Meier analysis. Results: Siglec-15 expression was detected in 50.7% of tumor samples and 36.4% of TAMs. Membranous expression was significantly associated with tumor differentiation, with higher expression observed in moderately differentiated tumors (P = 0.048), while cytoplasmic and TAM expression showed no significant associations with clinical variables. Although not statistically significant, positive Siglec-15 expression-both membranous and cytoplasmic-was associated with shorter median overall survival (cytoplasmic: 30.62 vs. 74.92 months, P = 0.1790; membranous: 39.44 vs. 66.07 months, P = 0.5761). Established prognostic indicators such as age, clinical stage, and pT stage were significantly associated with overall survival. Conclusion: Siglec-15 is frequently expressed in gastric cancer and may contribute to immune evasion within the tumor microenvironment. Although no significant association with prognosis was found, its high expression underscores its potential as a novel immunotherapeutic target. Further studies are warranted to validate these findings and explore Siglec-15 clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.